表紙
市場調査レポート

X連鎖無ガンマグロブリン血症:世界の治験レビュー

X-Linked Agammaglobulinemia Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 318814
出版日 ページ情報 英文 65 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
X連鎖無ガンマグロブリン血症:世界の治験レビュー X-Linked Agammaglobulinemia Global Clinical Trials Review, H2, 2014
出版日: 2014年10月31日 ページ情報: 英文 65 Pages
概要

当レポートでは、X連鎖無ガンマグロブリン血症の臨床試験に関連する基本情報やデータを提供しており、試験件数および被験者の募集状況、段階別の動向、臨床試験を実施している主な製薬企業および研究機関のプロファイルなどを提供しています。

イントロダクション

  • X連鎖無ガンマグロブリン血症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:免疫疾患治療薬の治験におけるX連鎖無ガンマグロブリン血症の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:免疫疾患治療薬の治験におけるX連鎖無ガンマグロブリン血症の割合

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

X連鎖無ガンマグロブリン血症治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • CSL Limited
    • Bio Products Laboratory Ltd.
    • LFB S.A.
    • Kedrion Group S.p.A.
    • Grifols, S.A.
    • Baxter International Inc.
  • 代表的な研究機関・病院の治験の概要
    • Fairview University Medical Center
    • Sanquin Blood Supply Foundation
    • The National Institute of Allergy and Infectious Diseases
    • Federal University of Sao Paulo
    • Washington University School of Medicine
    • University of Alabama at Birmingham

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2415CTIDB

GlobalData's clinical trial report, "X-Linked Agammaglobulinemia Global Clinical Trials Review, H2, 2014" provides data on the X-Linked Agammaglobulinemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on X-Linked Agammaglobulinemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating X-Linked Agammaglobulinemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • X-Linked Agammaglobulinemia
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in X-Linked Agammaglobulinemia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • CSL Limited
      • Clinical Trial Overview of CSL Limited
      • Bio Products Laboratory Ltd.
      • Clinical Trial Overview of Bio Products Laboratory Ltd.
      • LFB S.A.
      • Clinical Trial Overview of LFB S.A.
      • Kedrion Group S.p.A.
      • Clinical Trial Overview of Kedrion Group S.p.A.
      • Grifols, S.A.
      • Clinical Trial Overview of Grifols, S.A.
      • Baxter International Inc.
      • Clinical Trial Overview of Baxter International Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • Fairview University Medical Center
      • Clinical Trial Overview of Fairview University Medical Center
      • Sanquin Blood Supply Foundation
      • Clinical Trial Overview of Sanquin Blood Supply Foundation
      • The National Institute of Allergy and Infectious Diseases
      • Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases
      • Federal University of Sao Paulo
      • Clinical Trial Overview of Federal University of Sao Paulo
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
      • University of Alabama at Birmingham
      • Clinical Trial Overview of University of Alabama at Birmingham
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Region, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials, G7 Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials, E7 Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • X-Linked Agammaglobulinemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by CSL Limited, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Bio Products Laboratory Ltd., 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by LFB S.A., 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Kedrion Group S.p.A., 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Grifols, S.A., 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Baxter International Inc., 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanquin Blood Supply Foundation, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Alabama at Birmingham, 2014*

List of Figures

  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials, G7 Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of X-Linked Agammaglobulinemia to Immunology Clinical Trials, E7 Countries (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • X-Linked Agammaglobulinemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • X-Linked Agammaglobulinemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top